- Home
- ERNA vs JAGX Comparison
ERNA vs JAGX Comparison
Compare ERNA & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- JAGX
- Stock Information
- Founded
- ERNA 2018
- JAGX 2013
- Country
- ERNA United States
- JAGX United States
- Employees
- ERNA N/A
- JAGX N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- ERNA Health Care
- JAGX Health Care
- Exchange
- ERNA Nasdaq
- JAGX Nasdaq
- Market Cap
- ERNA 15.8M
- JAGX 12.9M
- IPO Year
- ERNA N/A
- JAGX N/A
- Fundamental
- Price
- ERNA $0.31
- JAGX $0.86
- Analyst Decision
- ERNA
- JAGX
- Analyst Count
- ERNA 0
- JAGX 0
- Target Price
- ERNA N/A
- JAGX N/A
- AVG Volume (30 Days)
- ERNA 662.5K
- JAGX 311.0K
- Earning Date
- ERNA 03-13-2025
- JAGX 03-31-2025
- Dividend Yield
- ERNA N/A
- JAGX N/A
- EPS Growth
- ERNA N/A
- JAGX N/A
- EPS
- ERNA N/A
- JAGX N/A
- Revenue
- ERNA $598,000.00
- JAGX $10,480,000.00
- Revenue This Year
- ERNA N/A
- JAGX $18.18
- Revenue Next Year
- ERNA N/A
- JAGX $40.06
- P/E Ratio
- ERNA N/A
- JAGX N/A
- Revenue Growth
- ERNA 1072.55
- JAGX N/A
- 52 Week Low
- ERNA $0.22
- JAGX $0.78
- 52 Week High
- ERNA $2.63
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- ERNA 44.59
- JAGX 45.91
- Support Level
- ERNA $0.25
- JAGX $0.78
- Resistance Level
- ERNA $0.37
- JAGX $1.03
- Average True Range (ATR)
- ERNA 0.04
- JAGX 0.07
- MACD
- ERNA -0.00
- JAGX 0.01
- Stochastic Oscillator
- ERNA 54.08
- JAGX 30.44
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.